Aquestive Therapeutics, Inc.
AQST· Nasdaq
AQSTAquestive Therapeutics, Inc.
Filed Mar 5, 2024 · 10-K · 65 days after period end · 0001628280-24-009010
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 |
|---|---|---|---|---|
| Revenue | $13.21M | $10.68M | $11.08M | $7.15M |
| Net Income | -$8.11M | -$12.35M | -$28.95M | -$20.37M |
| EPS Diluted | — | — |
Aquestive Therapeutics, Inc. · CIK 1398733 · Engraved from SEC EDGAR
| — |
| -$0.60 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2023 · filed Mar 5, 2024 · 65 d after period end
